Bill Anderson, Bayer CEO (Dia Dipasupil/Getty Images)
Bayer not eyeing new deals to address Xarelto sales erosion
Bayer reiterated its plans to ride out the generic-driven sales decline of its thrombosis drug Xarelto, as the company’s shares plummeted to a record low …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
